None listed
Conditions
Brief summary
This is an observational cohort study assessing the serological response to COVID-19 vaccination in kidney and kidney pancreas transplant recipients and patients treated with maintenance dialysis at Auckland City Hospital. Three analyses will be undertaken: 1. Vaccine immunogenicity based on humoral and cellular responses. Serological testing for the antibody to SARS-CoV-2 will be done prior to vaccination and again at 1 and 3 weeks and 6 months after the booster vaccination in dialysis and transplant recipients. Cellular responses will be assessed at 3 weeks after the booster vaccination. 2. Development of anti-HLA antibodies in dialysis patients on the kidney transplant waiting list in the first 12 months after vaccination. 3. Development of acute rejection episodes at 1, 4, 8 and 12 weeks after vaccination in recipients of kidney and kidney-pancreas transplants.
Interventions
Assessment of serology for Covid -19 vaccination in kidney transplant and dialysis patients
Testing at 1 and 3 weeks post Covid Vaccination and 6 months post covid vaccination
follow up for one year with graft survival
Sponsors
Auckland District Health Board
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
o Adults aged 16 years and older. o Patients with kidney failure on dialysis o Kidney-only and simultaneous pancreas kidney transplant recipients, who are at least 3 months post transplantation. o Planned to receive a vaccine for SARS-CoV-2
Exclusion criteria
o Patients with current COVID-19 infection o Patients with a proven current bacterial, viral, fungal or parasitic infection o Pregnant o Unable to give informed consent o Refuse to get vaccinated
Outcome results
None listed